Showing results (1221-1230 of 5,986) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|January 14, 2022
Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In VivoJohannes Doerner, Erwan Sallard, Wenli Zhang, et al.
Molecular Cancer Therapeutics|July 28, 2019
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target ToxicityRené Bartz, Keisuke Fukuchi, Toshiaki Ohtsuka, et al.
Molecular Cancer Therapeutics|August 28, 2022
Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term SurvivalHong Wang, Vinayak Khattar, Jonathan A Hensel, et al.
Molecular Cancer Therapeutics|August 28, 2022
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell DeathWilliam A Blessing, Christopher S Digesu, Rong Liu, et al.
Molecular Cancer Therapeutics|October 5, 2021
NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor MicroenvironmentTiange Dong, Priyal Dave, EunJeong Yoo, et al.
Molecular Cancer Therapeutics|January 28, 2022
Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEsMara Gilardi, Robert Saddawi-Konefka, Victoria H Wu, et al.
Molecular Cancer Therapeutics|May 17, 2019
17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer CellsSheng Dai, Shu Yang, Xin Hu, et al.
Molecular Cancer Therapeutics|April 26, 2019
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerShweta Joshi, Alok R Singh, Kevin X Liu, et al.
Molecular Cancer Therapeutics|August 24, 2018
Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1-S Phase Progression in Human Glioblastoma Stem CellsMarta Peretti, Federica Maddalena Raciti, Valentina Carlini, et al.
Molecular Cancer Therapeutics|May 2, 2019
The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-CateninSamriddhi Shukla, David Milewski, Arun Pradhan, et al.
Pageof 599